公开(公告)号：EP0595924A4

公开(公告)日：1994-08-24

申请号：EP92915895

申请日：1992-07-14

Applicant: ABBOTT LAB

Inventor： SUMMERS JAMES B ,  DAVIDSEN STEVEN K ,  HOLMS JAMES H ,  PIREH DAISY ,  HEYMAN H ROBIN ,  MARTIN MICHAEL B ,  STEINMAN DOUGLAS H ,  SHEPPARD GEORGE S ,  CARRERA GEORGE M JR

IPC: A61K31/44 ,  A61K31/4406 ,  A61K49/00 ,  A61K49/06 ,  A61P1/04 ,  A61P7/02 ,  A61P7/06 ,  A61P9/02 ,  A61P11/06 ,  A61P17/06 ,  A61P29/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07B47/00 ,  C07D213/69 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07F5/00 ,  C07F13/00

CPC classification number: C07D487/04 ,  A61K49/06 ,  C07D213/69 ,  C07D513/04

公开(公告)号：EP0574494A4

公开(公告)日：1994-07-06

申请号：EP92906944

申请日：1992-02-14

Applicant: ABBOTT LAB

Inventor： SUMMERS JAMES B ,  SHEPPARD GEORGE S ,  PHILLIPS JAMES G ,  PIREH DAISY ,  STEINMAN DOUGLAS H ,  MAY PAUL D ,  GUINN DENISE E ,  HEYMAN H ROBIN ,  CARRERA GEORGE M JR ,  DAVIDSEN STEVEN K

IPC: A61K31/44 ,  A61K31/4427 ,  A61K31/4433 ,  A61P7/02 ,  A61P11/00 ,  A61P29/00 ,  C07D401/14 ,  C07D403/14 ,  C07D409/14 ,  C07D417/14

CPC classification number: C07D409/14 ,  C07D417/14

公开(公告)号：ES2196190T3

公开(公告)日：2003-12-16

申请号：ES96940406

申请日：1996-11-13

Applicant: ABBOTT LAB

Inventor： FESIK STEPHEN W ,  SUMMERS JAMES B JR ,  DAVIDSEN STEVEN K ,  SHEPPARD GEORGE S ,  STEINMAN DOUGLAS H ,  CARRERA GEORGE M JR

IPC: A61P19/02 ,  A61K31/185 ,  A61K31/275 ,  A61P29/00 ,  A61P35/04 ,  A61P43/00 ,  C07C259/06 ,  C07C323/60 ,  A61K31/16

Abstract: Compounds of formula or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF alpha secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF alpha secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF alpha secretion.

公开(公告)号：PT874808E

公开(公告)日：2003-08-29

申请号：PT96940406

申请日：1996-11-13

Applicant: ABBOTT LAB

Inventor： STEINMAN DOUGLAS H ,  FESIK STEPHEN W ,  SHEPPARD GEORGE S ,  CARRERA GEORGE M JR ,  SUMMERS JAMES B JR ,  DAVIDSEN STEVEN K ,  HOLMS JAMES H ,  FLORJANCIC ALAN

IPC: A61P19/02 ,  A61K31/185 ,  A61K31/275 ,  A61P29/00 ,  A61P35/04 ,  A61P43/00 ,  C07C259/06 ,  C07C323/60 ,  A61K31/16

Abstract: Compounds of formula or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF alpha secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF alpha secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF alpha secretion.

公开(公告)号：ES2153360T3

公开(公告)日：2001-03-01

申请号：ES92912971

申请日：1992-05-28

Applicant: ABBOTT LAB

Inventor： GARVEY DAVID S ,  CARRERA GEORGE M JR ,  ARNERIC STEPHEN P ,  SHUE YOUE-KONG ,  LIN NAN-HORNG ,  HE YUN

IPC: A61K31/40 ,  A61K31/415 ,  A61K31/42 ,  A61K31/422 ,  A61K31/425 ,  A61K31/427 ,  A61K31/44 ,  A61P25/00 ,  A61P25/22 ,  A61P25/28 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Novel isoxazole isothiazole and pyrazole compounds of the formula: wherein A, R1, and R2 are specifically defined, or pharmaceutical salts thereof, are selective and potent cholinergic ligands at neuronal nicotinic receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function, as well as in the treatment of alcohol intoxication and petit real absence epilepsy.

公开(公告)号：CA2109585C

公开(公告)日：2000-02-15

申请号：CA2109585

申请日：1992-05-28

Applicant: ABBOTT LAB

Inventor： GARVEY DAVID S ,  CARRERA GEORGE M JR ,  ARNERIC STEPHEN P ,  SHUE YOUE-KONG ,  LIN NAN-HORNG ,  HE YUN

IPC: A61K31/40 ,  A61K31/415 ,  A61K31/42 ,  A61K31/422 ,  A61K31/425 ,  A61K31/427 ,  A61K31/44 ,  A61P25/00 ,  A61P25/22 ,  A61P25/28 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  A61K31/41

Abstract: Selective and potent nicotinic agonists of formula (1), or pharmaceuticallyacceptable salts thereof, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.

公开(公告)号：AU690620B2

公开(公告)日：1998-04-30

申请号：AU1303695

申请日：1994-12-08

Applicant: ABBOTT LAB

Inventor： SUMMERS JAMES B JR ,  DAVIDSEN STEVEN K ,  CURTIN MICHAEL L ,  HEYMAN H ROBIN ,  SHEPPARD GEORGE S ,  XU LIANHONG ,  CARRERA GEORGE M JR ,  GARLAND ROBERT B

IPC: C07D487/04 ,  A61K31/41 ,  A61K31/425 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/505 ,  A61P7/02 ,  A61P11/00 ,  A61P11/16 ,  A61P17/00 ,  A61P29/00 ,  A61P37/08 ,  C07D401/12 ,  C07D403/10 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  A61K31/50

Abstract: The present invention relates to compounds of formula and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

公开(公告)号：CA2112562A1

公开(公告)日：1993-02-04

申请号：CA2112562

申请日：1992-07-14

Applicant: ABBOTT LAB

Inventor： SUMMERS JAMES B ,  DAVIDSEN STEVEN K ,  HOLMS JAMES H ,  PIREH DAISY ,  HEYMAN H ROBIN ,  MARTIN MICHAEL B ,  STEINMAN DOUGLAS H ,  SHEPPARD GEORGE ,  CARRERA GEORGE M JR

IPC: A61K31/44 ,  A61K31/4406 ,  A61K49/00 ,  A61K49/06 ,  A61P1/04 ,  A61P7/02 ,  A61P7/06 ,  A61P9/02 ,  A61P11/06 ,  A61P17/06 ,  A61P29/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07B47/00 ,  C07D213/69 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07F5/00 ,  C07F13/00 ,  A61K31/495 ,  A61K31/535 ,  A61K31/54

Abstract: 2112562 9301813 PCTABS00019 Indole compounds substituted at the 3-position by a 7-carbonyl(pyridin-3-yl)pyrrolo¢1,2-c!thiazole, 7-carbonyl(pyridin-3-yl)pyrrolo¢1,2-c!oxazoline, or 7-carbonyl(pyridin-3-yl)pyrrolo¢1,2-c!pyrrole group are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

公开(公告)号：DK0595924T3

公开(公告)日：1999-11-01

申请号：DK92915895

申请日：1992-07-14

Applicant: ABBOTT LAB

Inventor： SUMMERS JAMES B ,  DAVIDSEN STEVEN K ,  HOLMS JAMES H ,  PIREH DAISY ,  HEYMAN H ROBIN ,  MARTIN MICHAEL B ,  STEINMAN DOUGLAS H ,  SHEPPARD GEORGE S ,  CARRERA GEORGE M JR

IPC: A61K31/44 ,  A61K31/4406 ,  A61K49/00 ,  A61K49/06 ,  A61P1/04 ,  A61P7/02 ,  A61P7/06 ,  A61P9/02 ,  A61P11/06 ,  A61P17/06 ,  A61P29/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07B47/00 ,  C07D213/69 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07F5/00 ,  C07F13/00

Abstract: PCT No. PCT/US92/05890 Sec. 371 Date Dec. 2, 1993 Sec. 102(e) Date Dec. 2, 1993 PCT Filed Jul. 14, 1992 PCT Pub. No. WO93/01813 PCT Pub. Date Feb. 4, 1993.Indole compounds substituted at the 3-position by a 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]thiazole, 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]oxazole, or 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]pyrrole group are potent antagionists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointesinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

公开(公告)号：PT100525B

公开(公告)日：1999-10-29

申请号：PT10052592

申请日：1992-05-28

Applicant: ABBOTT LAB

Inventor： GARVEY DAVID S ,  SHUE YOUE-KONG ,  ARNERIC STEPHEN P ,  LIN NAN-HORNG ,  CARRERA GEORGE M JR ,  HE YUN

IPC: A61K31/415 ,  A61K31/42 ,  A61K31/422 ,  A61K31/425 ,  A61K31/40 ,  A61K31/427 ,  A61K31/44 ,  A61P25/00 ,  A61P25/22 ,  A61P25/28 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Novel isoxazole isothiazole and pyrazole compounds of the formula: wherein A, R1, and R2 are specifically defined, or pharmaceutical salts thereof, are selective and potent cholinergic ligands at neuronal nicotinic receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function, as well as in the treatment of alcohol intoxication and petit real absence epilepsy.